Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stagezero Life Sciences Ltd (OP: SZLSF )

0.0500 UNCHANGED
Streaming Delayed Price Updated: 1:17 PM EDT, Sep 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0500
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0500
Today's Range 0.0500 - 0.0500
52wk Range 0.0015 - 0.9999
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade Order
Via ACCESSWIRE
StageZero Life Sciences Announces Update on Filing of Full Year 2023 financials under the Failure to File Cease Trade Order
Via ACCESSWIRE

Performance

YTD
+47.93%
+47.93%
1 Month
+66.67%
+66.67%
3 Month
+140.38%
+140.38%
6 Month
+58.73%
+58.73%
1 Year
+23.76%
+23.76%

More News

Read More
StageZero Life Sciences Announces Update on Failure to File Cease Trade Order
Via ACCESSWIRE
StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational Update
Via ACCESSWIRE
StageZero Life Sciences Partners with My One Medical Source and 1,000+ Medical Access Points in the USA
Via ACCESSWIRE
StageZero Life Sciences' Clinical Business Introduces Fourth Pillar to Cancer Offerings
Via ACCESSWIRE
StageZero Life Sciences’ Clinical Business Introduces Third Pillar to Cancer Offerings
Via ACCESSWIRE
StageZero Life Sciences Provides an Update on Application for Management Cease Trade Order
Via ACCESSWIRE
StageZero Life Sciences Announces Delay to Fourth Quarter and Year End 2023 Financial Results
Via ACCESSWIRE
StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update
Via ACCESSWIRE
StageZero Life Sciences Announces Extension of Warrants Expiring in January 2023
Via ACCESSWIRE
StageZero Announces Solutions for Employers to Help Improve Cancer Outcomes
Via ACCESSWIRE
StageZero Life Sciences, Ltd Announces Q3 2022 Financial Results and Operational Update
Via ACCESSWIRE
StageZero to Hold Q3 2022 Operational and Financial Results Conference Call on Tuesday November 15, 2022
Via ACCESSWIRE
StageZero Life Sciences, Ltd Announces Q2 2022 Financial Results and Operational Update
Via ACCESSWIRE
StageZero to Hold Q2 2022 Operational and Financial Results Conference Call on Tuesday August 16, 2022
Via ACCESSWIRE
StageZero Life Sciences Announces Results on Resolutions at Annual and Special Meeting
From StageZero Life Sciences Ltd
Via AccessWire
StageZero Life Sciences Announces Resignation of CFO
From StageZero Life Sciences Ltd
Via AccessWire
StageZero Life Sciences Partners With DiagnoseAtHome To Offer Multi-Cancer Blood Test
Via Benzinga
StageZero Life Sciences Partners with DiagnoseAtHome to Offer Aristotle(R) Multi-Cancer Blood Test in Canada and USA
From StageZero Life Sciences Ltd
Via AccessWire
StageZero Life Sciences, Ltd Announces Q1 2022 Financial Results and Operational Update
From StageZero Life Sciences Ltd
Via AccessWire
Exposures COVID-19
StageZero Life Sciences Launches COC Plus Worldwide
From StageZero Life Sciences Ltd
Via AccessWire
StageZero to Issue Q1 2022 Financial Results and Hold Conference Call on Tuesday May 17
From StageZero Life Sciences Ltd
Via AccessWire
StageZero Life Sciences, Ltd Announces Corporate Update
From StageZero Life Sciences Ltd
Via AccessWire
StageZero Life Sciences, Ltd Announces Q4 2021 and Year End Financial Results and Operational Update
From StageZero Life Sciences Ltd
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.